铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究  

Clinical trial of hydrotalcite tablets combined with esomeprazole magnesium enteric-coated tablets in the treatment of active gastric ulcer with Helicobacter pylori infection

作　　者：赖人旭[1] 任江南[1] 苟新敏[2] 高敏照[1] 麦蕾[1] 郭惠学[1] 

机构地区：[1]中山大学附属第五医院消化内科,广东珠海519000 [2]中山大学附属第五医院病理科,广东珠海519000

出　　处：《中国临床药理学杂志》2017年第19期1868-1870,共3页The Chinese Journal of Clinical Pharmacology

基　　金：广东省科技厅科技计划基金资助项目(2016ZC0022)

摘　　要：目的观察铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌(Hp)感染合并活动性胃溃疡的临床疗效及安全性。方法将87例Hp感染合并活动性胃溃疡患者随机分为对照组44例和试验组43例。对照组予以埃索美拉唑肠溶片20 mg,qd,口服;试验组在对照组治疗的基础上,予以铝碳酸镁片每次1 g,tid,口服。2组患者均治疗4周。比较2组患者的临床疗效、Hp根除率、愈合质量,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为90.70%(39/43例)和88.64%(39/44例),Hp根除率分别为81.40%(35/43例)和77.27%(34/44例),差异均无统计学意义(均P>0.05)。治疗后,试验组和对照组的愈合质量(优级)分别为65.12%(28/43例)和40.91%(18/44例),差异有统计学意义(P<0.05)。试验组发生的药物不良反应有食欲缺乏、头晕、反胃,对照组发生的药物不良反应有食欲缺乏和反胃。试验组和对照组的总药物不良反应发生率分别为13.95%和11.36%,差异无统计学意义(P>0.05)。结论铝碳酸镁片联合埃索美拉唑肠溶片治疗Hp感染合并活动性胃溃疡的临床疗效和安全性与单用埃索美拉唑肠溶片相似,但前者可显著提高患者溃疡的愈合质量。Objective To observe the clinical efficacy and safety of hydrotalcite tablets combined with esomeprazole magnesium enteric-coated tablets in the treatment of active gastric ulcer with Helicobacter pylori（ Hp） infection. Methods A total of 87 cases of active gastric ulcer with Hp infection were randomly divided into control group（ n = 44 cases） and treatment group（ n = 43 cases）. Control group was treated with esomeprazole enteric coated tablet 20 mg,qd,orally. Treatment group was given hydrotalcite tablets 1 g each time,tid,orally. The two groups were treated for 4 weeks. The clinical efficacy,Hp eradication rate,healing quality and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 90. 70%（ 39/43 cases） and 88. 64%（ 39/44cases）,the eradication rates of Hp were 81. 40%（ 35/43 cases） and77. 27%（ 34/44 cases）, there were no significant differences（ all P〈0. 05）. After treatment,the healing quality of treatment group andcontrol group（ grade） were 65. 12%（ 28/43 cases） and 40. 91%（ 18/44 cases） with significant difference（ P〈0. 05）. The adverse drug reactions in the treatment group were based on anorexia,dizziness and nausea,which in control group were based on lack of appetite and nausea. The incidences of adverse drug reactions in treatment and control groups were 13. 95% and 11. 36% without significant difference（ P〉0. 05）. Conclusion There were the same clinical efficacy and safety in the treatment of active gastric ulcer with Hp infection between hydrotalcite tablet combined with esomeprazole enteric coated tablet and single use of esomeprazole magnesium enteric-coated tablet,but the former can significantly improve the quality of ulcer healing.

关 键 词：铝碳酸镁片 埃索美拉唑肠溶片 幽门螺杆菌 活动性胃溃疡 

分 类 号：R975[医药卫生—药品]